Biogen
BIIB
965 hedge funds and large institutions have $32.2B invested in Biogen in 2023 Q3 according to their latest regulatory filings, with 91 funds opening new positions, 334 increasing their positions, 346 reducing their positions, and 118 closing their positions.
11% more call options, than puts
Call options by funds: $575M | Put options by funds: $517M
3% less repeat investments, than reductions
Existing positions increased: 334 | Existing positions reduced: 346
1.3% less ownership
Funds ownership: 87.59% → 86.3% (-1.3%)
4% less funds holding
Funds holding: 1,008 → 965 (-43)
11% less capital invested
Capital invested by funds: $36.1B → $32.2B (-$3.96B)
17% less funds holding in top 10
Funds holding in top 10: 18 → 15 (-3)
23% less first-time investments, than exits
New positions opened: 91 | Existing positions closed: 118
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$363M |
| 2 |
JP Morgan Chase
New York
|
+$138M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$80.3M |
| 4 |
VanEck Associates
New York
|
+$62.6M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$55.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$342M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$172M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$154M |
| 4 |
D.E. Shaw & Co
New York
|
-$152M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$91.2M |
BIIB Hedge Fund Activity: Q3 2023 in Review
965 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2023, worth a combined $32.2B — down 11% from $36.1B a quarter earlier.
Sellers outnumbered buyers: 118 funds closed out of BIIB and 91 opened new positions — a net loss of 27 holders — while 346 trimmed existing stakes and 334 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $363M. The largest seller was Fidelity Investments, cutting an estimated $342M.
- 965 institutional investors held Biogen (BIIB) as of Q3 2023, down from 1,008 in Q2 2023.
- Funds reported $32.2B of Biogen stock for Q3 2023, down 11% quarter-over-quarter.
- 91 funds opened new Biogen positions in Q3 2023 and 118 closed out, a net change of -27 holders.
- The largest Biogen buyer in Q3 2023 was T. Rowe Price Investment Management, an estimated $363M added.
- The largest Biogen seller in Q3 2023 was Fidelity Investments, an estimated $342M sold.
Based on aggregated 13F filings for Q3 2023.